Takeda: Hematologic Diseases trials
The registry lists 11 Hematologic Diseases studies with Takeda as lead sponsor. 2 are open to participants now and 9 have results posted.
Phase 1 2Phase 2 3Phase 3 6Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06948318Phase 3
- A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06722235Phase 3
- A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedNCT02627677Phase 3Results posted
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
- A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 4Results posted
- A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
- Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
- A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2Results posted
- Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)TerminatedNCT01650805Phase 3Results posted
- Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia ATerminatedNCT01434511Phase 3Results posted
- Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia ACompletedNCT01178294Phase 2/3Results posted